	On July 1, 2016, CordenPharma announced that it has expanded its services to include oligonucleotide API development and manufacturing. The investment was initiated by CordenPharma Colorado and is expected to be complete before the end of 2016, the company said in a 

 Corden’s portfolio for API and drug products includes peptides, lipids, and carbohydrates for API manufacturing and development. In late June, the Italian Medicines Agency 

 Corden’s sterile injectable facility in Caponago, Italy. The manufacturing facility, which was recently completed, will support customer development and commercial programs by providing service in aseptic filling of liquid and lyophilized vials, and pre-filled syringes. This adds to the facility’s existing terminal sterilization capabilities.

Contract Manufacturing, Finished Drug Product

Manufacturing Services

Outsourcing

PharmTech News

Supplier News

PTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016

The company expanded its services to include oligonucleotide API development and manufacturing and received approval for its Caponago manufacturing facility.